BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Graft-versus-host disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for graft vs host disease: 62 (42 sponsors; 8 newly posted in the last 180 days, 5 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 8.9, rank 78 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 7, Phase 2 24, Phase 3 13, Phase 4 6, N/A 10.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Incyte Corporation INCY | 7 | NA 1, P3 3, P2 3 | 0 | 1 |
| Sanofi SNY | 5 | P2 1, P4 1, P3 2, P1 1 | 2 | 1 |
| Dompé Farmaceutici S.p.A | 2 | P3 2 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | P2 2, P3 1 | 0 | 0 |
| medac GmbH | 2 | P2 1, P3 1 | 0 | 0 |
| Regenerative Ocular Immunobiologics LLC | 2 | P3 1, P2 1 | 1 | 2 |
| Incyte Biosciences Japan GK INCY | 1 | P3 1 | 0 | 0 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 1 |
| Mesoblast, Ltd. MESO | 1 | P3 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 5 | P2 1, NA 1, P4 3 | 0 | 0 |
| Ausper Biopharma Co., Ltd. new entrant | 2 | P1 1, P2 1 | 2 | 0 |
| Abbisko Therapeutics Co, Ltd | 1 | P2 1 | 0 | 0 |
| Beijing Tide Pharmaceutical Co., Ltd | 1 | P2 1 | 0 | 0 |
| Bellicum Pharmaceuticals | 1 | P2 1 | 0 | 0 |
| Biokosmes Srl | 1 | NA 1 | 0 | 0 |
| BioPhoenix Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Cellenkos, Inc. | 1 | P2 1 | 0 | 0 |
| Cision Vision, Inc. new entrant | 1 | NA 1 | 1 | 0 |
| Curonix LLC | 1 | NA 1 | 0 | 0 |
| Daewoong Pharmaceutical Co. LTD. | 1 | NA 1 | 0 | 0 |
| Deciphera Pharmaceuticals, LLC | 1 | P2 1 | 0 | 0 |
| Dr. Reddy's Laboratories Limited, India new entrant | 1 | P1 1 | 1 | 1 |
| Enterra Medical, Inc. | 1 | NA 1 | 0 | 0 |
| Grand Theravac Life Sciences (Hangzhou) Co., Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| Grit Biotechnology | 1 | EARLY_P1 1 | 0 | 0 |
New-entrant sponsors: Ausper Biopharma Co., Ltd., Cision Vision, Inc., Dr. Reddy's Laboratories Limited, India, Grand Theravac Life Sciences (Hangzhou) Co., Ltd..
Recently stopped trials
- NCT04313725 Tangible Science - terminated: Slow enrollment and difficulty getting patients to complete the study visits (significantly impacted by COVID-19 pandemic) Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
- NCT05643638 Cynata Therapeutics Limited - terminated: Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not de A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
- NCT03805789 CSL Behring - terminated: Sponsor Decision The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients
- NCT04640025 Incyte Corporation - terminated: The decision to close the study was made due to the expiration of remaining drug supply. A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- NCT04941404 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - terminated: This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns. A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | ReAlta Life Sciences, Inc. | NCT06343792 Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease | Steroid Refractory GVHD | recruiting | 66 |
| 2026-12 est. | P1/P2 | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | NCT06677255 A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment | Steroid-refractory Acute Graft-versus-host Disease | not yet recruiting | 149 |
| 2026-12-31 est. | P3 | Janssen Research & Development, LLC | NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; | active not recruiting | 539 |
| 2027-01-06 est. | P1/P2 | Incyte Corporation INCY | NCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Chronic Graft-versus-host-disease | active not recruiting | 32 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-30 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06941350 A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD | Acute Graft-versus-Host Disease | not yet recruiting | 24 |
| 2026-10-01 | P2 | Incyte Corporation INCY | NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | active not recruiting | 130 |
| 2026-08-31 est. | P2 | Kadmon, a Sanofi Company | NCT05567406 Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and F | Chronic Graft Versus Host Disease | withdrawn |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "graft vs host disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.